p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin

被引:31
作者
Lam, VT
McPherson, JP
Salmena, L
Lees, J
Chu, W
Sexsmith, E
Hedley, DW
Freedman, MH
Reed, JC
Malkin, D
Goldenberg, GJ
机构
[1] Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada
[3] Univ Toronto, Interdepartmental Div Oncol, Toronto, ON M5S 1A8, Canada
[4] Ontario Canc Inst, Dept Med, Toronto, ON M4X 1K9, Canada
[5] Ontario Canc Inst, Dept Pathol, Toronto, ON M4X 1K9, Canada
[6] Burnham Inst, La Jolla, CA 92037 USA
[7] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada
关键词
p53; acute lymphoblastic leukemia; drug resistance; adriamycin; apoptosis;
D O I
10.1016/S0145-2126(99)00102-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of p53 as a determinant of sensitivity of ten childhood acute lymphoblastic leukemia (ALL) cell lines to Adriamycin (ADR) was investigated. ADR-sensitive cell lines were found to have wild-type (wt) p53, whereas resistant cell lines contained point mutations in the gene. The basal level of wt p53 protein in sensitive cells was lower than that of mutant p53 in resistant cells, however, after ADR treatment a 6- to 20-fold dose-dependent increase in wt p53 was observed, whereas-mutant p53 increased only twofold. The percentage of apoptotic cells in ADR-sensitive lines with wt p53 ranged from 43 to 93% following ADR treatment, whereas that in resistant lines with mutant p53 was only 8-13%. The ratio of constitutive levels of Bax/Bcl-2 was significantly higher in cells containing wt p53 than in cells with mutant p53. These results suggest that p53 gene status and the ability of p53 to induce apoptosis may be determinants of sensitivity to ADR in childhood ALL cells. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:871 / 880
页数:10
相关论文
共 49 条
[1]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[2]   p53 in signaling checkpoint arrest or apoptosis [J].
Bates, S ;
Vousden, KH .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) :12-18
[3]   Exon 5 mutations in the P53 gene in relapsed childhood acute lymphoblastic leukemia [J].
Blau, O ;
Avigad, S ;
Stark, B ;
Kodman, Y ;
Luria, D ;
Cohen, IJ ;
Zaizov, R .
LEUKEMIA RESEARCH, 1997, 21 (08) :721-729
[4]  
BROWN GA, 1995, CANCER RES, V55, P78
[5]   P53 MUTATIONS ARE COMMON AND EARLY EVENTS THAT PRECEDE TUMOR INVASION IN SQUAMOUS-CELL NEOPLASIA OF THE SKIN [J].
CAMPBELL, C ;
QUINN, AG ;
RO, YS ;
ANGUS, B ;
REES, JL .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 100 (06) :746-748
[6]  
CAMPOS L, 1993, BLOOD, V81, P3091
[7]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[8]   MULTIFACTORIAL RESISTANCE TO ANTINEOPLASTIC AGENTS IN DRUG-RESISTANT P388 MURINE LEUKEMIA, CHINESE-HAMSTER OVARY, AND HUMAN HELA-CELLS, WITH EMPHASIS ON THE ROLE OF DNA TOPOISOMERASE-II [J].
DEFFIE, AM ;
MCPHERSON, JP ;
GUPTA, RS ;
HEDLEY, DW ;
GOLDENBERG, GJ .
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1992, 70 (05) :354-364
[9]  
DEFFIE AM, 1988, CANCER RES, V48, P3595
[10]  
DICCIANNI MB, 1994, BLOOD, V84, P3105